A New York federal court dismissed a class action lawsuit involving the LIBRA and M3M3 crypto token launches, without deciding on allegations of market manipulation or fraud. The judge denied the plaintiffs' request to amend their complaint, citing insufficient evidence that Meteora was a suable entity and that fraud claims did not meet legal standards. This ruling focuses on the adequacy of the legal claims rather than the factual conduct of the launches. The case closure leaves the allegations unresolved but halts further legal action for now.
The New York court ruling on the LIBRA and M3M3 class action lawsuit provides context for crypto market observers. For readers following cryptocurrency trends, here is Pluang's market snapshot as of Oct 01, 2026 12:12 WIB: out of 50 major cryptocurrencies priced on Pluang, 37 rose and 12 fell. Notable movers include EGLD at Rp84.244 with a 5.70% increase and a typical hold time of 85 days, ATOM at Rp32.083 up 4.27%, and AAVE at Rp2.980.254 rising 3.93%.
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
TDG Gold Corp. has agreed to sell a 51% interest in its Aurora West property to Freeport-McMoRan for C$110 million in cash. Freeport also has an option to increase its ownership to 75% or 100% by funding an additional C$80 million in exploration and ...
Union Station Homeless Services is requesting community help to donate 627 frozen turkeys for its annual Dinner in the Park event, aiming to serve 6,000 Thanksgiving meals. The turkey drive will be held on November 16-17 in Pasadena, California. Dona...
Timeplast, a materials company with over 9,000 customers, has launched a Regulation A+ offering open to the public to license its patented water-soluble plastic technology. This plastic dissolves in water after a programmed period, reducing plastic w...
DelveInsight's 2026 report highlights more than 100 BCMA-targeted therapies in various clinical stages, focusing on multiple myeloma and other diseases. Leading pharma companies like Pfizer, Regeneron, and AstraZeneca are advancing treatments includi...
